2013, Number 2
<< Back Next >>
Cir Cir 2013; 81 (2)
Endometriosis as a risk factor for ovarian cancer
Vargas-Hernández VM
Language: Spanish
References: 36
Page: 163-168
PDF size: 1039.96 Kb.
ABSTRACT
The history of endometriosis is a risk factor for some subtypes of epithelial ovarian cancer. Endometriosis is associated with increased risk of ovarian clear cell, serous low-grade endometrioid, but it is unclear role in the development of other histopathological subtypes of ovarian cancer as high-grade serous borderline tumors subtypes or borderline serous and mucinous as the understanding of the mechanisms leading to malignant transformation of endometriosis will be needed to identify subgroups of women at increased risk of ovarian cancer in the high prevalence and cause of infertility in Mexico and the world.
All factors must be considered during the decision making process for the treatment of endometriosis, including the rare malignant transformation.
REFERENCES
Tsin DA, Chuang L, Bradley WH, Schlosshauer, Nezhat F. Endometriosis y cáncer en Vargas-Hernández VM. Edit. 1ª. ed. Cáncer en la Mujer 1ª. Ed. Edit. Alfil México, 2011 p. 825-831.
Vargas-Hernández VM, Romo-Vázquez LM, Kably-Ambe A. Endometriosis. En Vargas-Hernández VM, editor. Histerectomía indicaciones, complicaciones y alternativas 1ª. Ed. Edit. DEMSA México, 2005 p. 205-215.
Montgomery GW, Nyholt DR, Zhao ZZ, Treloar SA, Painter JN, Missmer SA. The search for genes contributing to endometriosis risk. Hum Reprod Update 2008;14(5):447-457.
Kobayashi H. Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer. Reproductive Medicine and Biology 2010;9(1):17-22.
Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control 2008;19(10):1357-1364.
Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 2009;124(6):1409-1415.
Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122(1):170-176.
Melin A, Sparén P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 2006;21(5):1237-1242.
Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjaer SK, Graubard BI, et al. Relationship of Benign Gynecologic Diseases to Subsequent Risk of Ovarian and Uterine Tumors. Cancer Epidemiol Biomarkers Prev 2005:14:2929-2935.
Van Gorp T, Amant F, Neven P, Vergote I. Endometriosis and the development of malignant tumours of the pelvis: A review of the literature. Best Pract Res Clin Obstet Gynaecol 2004;18(2):349-371.
Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122(1):170-176.
Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control 2008;19(10):1357-1364.
Preciado-Ruiz R, Torres-Calleja J, Zuñiga-Montiel JA, Martínez- Chequer JC, Manterola-Álvarez D, García-Luna A. Incidence of endometriosis in infertile women: clinical and laparoscopic characteristics. Ginecol Obstet Mex 2005;73:471-476.
Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol 2012;13(4):385-394.
Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39(8):1239-1251.
Steffensen KD, Waldstrøm M, Grove A, Lund B, Pallisgård N, Jakobsen A. Improved Classification of Epithelial Ovarian Cancer. Results of 3 Danish Cohorts. Int J Gynecol Cancer 2011;21(9):1592-1600.
Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype. Am J Epidemiol 2010;171(1):45-53.
Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 2005;96(2):520-530.
Viganõ P, Somigliana E, Parazzini F, Vercellini P. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril 2007;88(3):588-593.
Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, et al. Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Res 2007;67:3027-3035.
Pearce CL, Wu AH, Gayther SA, Bale AE, Beck PA, Beesley J, et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. Br J Cancer 2008;98:282-288.
Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, et al. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicenter biobanking study. J Clin Epidemiol 2011;64:525-530.
Risch HA, Bale AE, Beck PA, Zheng W. PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1738-1741.
Lurie G, Terry KL, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 2010;21(10):1731-1741.
Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception Methods, Beyond Oral Contraceptives and Tubal Ligation, and Risk of Ovarian Cancer. Ann Epidemiol 2011;21(3):188-196.
Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, et al. Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer 2009;101:1461-1468.
Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal Women. Am J Epidemiol 2008;167(9):1059-1069.
Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen Receptor Cytosine, Adenine, Guanine Repeats, and Haplotypes in Relation to Ovarian Cancer Risk. Cancer Res 2005;65:5974-5981.
García-Closas M, Brinton LA, Lissowska J, Richesson D, Sherman ME, Szeszenia-Dabrowska N, et al. Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a populationbased case-control study. BMC Cancer 2007;7:60-67.
Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26(1):53-77.
Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 2012;26(2):243-256.
Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211(1):26-35.
Kurman RJ, Shih Ie-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm. Hum Pathol 2011;42(7):918-931.
Kurman RJ, Shih Ie-M. The Origin and Pathogenesis of Epithelial Ovarian Cancer- a Proposed Unifying Theory. Am J Surg Pathol 2010;34(3):433-443.
Sangoi AR, Soslow RA, Teng NN, Longacre TA. Ovarian Clear Cell Carcinoma With Papillary Features: A Potential Mimic of Serous Tumor of Low Malignant Potential. Am J Surg Pathol 2008;32(2):269-274.
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas. N Engl J Med 2010;363(16):1532-1543.